Related references
Note: Only part of the references are listed.Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial
Ganesh Kumar Rai et al.
LANCET INFECTIOUS DISEASES (2022)
Carrier Proteins Facilitate the Generation of Antipolysaccharide Immunity via Multiple Mechanisms
Fan Zhang et al.
MBIO (2022)
A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine (TyphiBEVTM) in healthy infants, children, and adults in comparison with a licensed comparator
Subhash Thuluva et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)
Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination
Krishna Mohan Vadrevu et al.
VACCINE (2021)
Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial
Mila Shakya et al.
Lancet Global Health (2021)
Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial
Firdausi Qadri et al.
LANCET (2021)
Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children
Priyanka D. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Comparison of Strategies for Typhoid Conjugate Vaccine Introduction in India: A Cost-Effectiveness Modeling Study
Theresa Ryckman et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Overview of the Nontyphoidal and Paratyphoidal Salmonella Vaccine Pipeline: Current Status and Future Prospects
Scott M. Baliban et al.
CLINICAL INFECTIOUS DISEASES (2020)
A Systematic Review on Antimicrobial Resistance among Salmonella Typhi Worldwide
Christian Marchello et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2020)
The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017
Jeffrey D. Stanaway et al.
LANCET INFECTIOUS DISEASES (2019)
The evolution of antimicrobial resistance in Salmonella Typhi
Abhilasha Karkey et al.
CURRENT OPINION IN GASTROENTEROLOGY (2018)
Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children
Maria Rosario Capeding et al.
VACCINE (2018)
Design and production of conjugate vaccines against S. Paratyphi A using an O-linked glycosylation system in vivo
Peng Sun et al.
NPJ VACCINES (2018)
Protection against Staphylococcus aureus Colonization and Infection by B- and T-Cell-Mediated Mechanisms
Fan Zhang et al.
MBIO (2018)
Potential targets for next generation antimicrobial glycoconjugate vaccines
Francesca Micoli et al.
FEMS MICROBIOLOGY REVIEWS (2018)
Safety and Immunogenicity of a Vi Polysaccharide-Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 Study
Vadrevu Krishna Mohan et al.
CLINICAL INFECTIOUS DISEASES (2015)
Safety and immunogenicity of an attenuated Salmonella enterica serovar Paratyphi A vaccine candidate
Kun Xiong et al.
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY (2015)
Carrier priming with CRM197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: Biophysical and immunochemical interpretation
S. Pecetta et al.
VACCINE (2015)
The Classical Lancefield Antigen of Group A Streptococcus Is a Virulence Determinant with Implications for Vaccine Design
Nina M. van Sorge et al.
CELL HOST & MICROBE (2014)
Serum Bactericidal Assays To Evaluate Typhoidal and Nontyphoidal Salmonella Vaccines
Mary Adetinuke Boyd et al.
CLINICAL AND VACCINE IMMUNOLOGY (2014)
lmmunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials
Zulfiqar A. Bhutta et al.
LANCET INFECTIOUS DISEASES (2014)
A scalable method for O-antigen purification applied to various Salmonella serovars
F. Micoli et al.
ANALYTICAL BIOCHEMISTRY (2013)
Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity
Fan Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
O:2-CRM197 Conjugates against Salmonella Paratyphi A
Francesca Micoli et al.
PLOS ONE (2012)
A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi
Ying-Jie Lu et al.
VACCINE (2012)
The Vi Conjugate Typhoid Vaccine Is Safe, Elicits Protective Levels of IgG Anti-Vi, and Is Compatible with Routine Infant Vaccines
Vu Dinh Thiem et al.
CLINICAL AND VACCINE IMMUNOLOGY (2011)
The Vi Capsular Polysaccharide Prevents Complement Receptor 3-Mediated Clearance of Salmonella enterica Serotype Typhi
R. Paul Wilson et al.
INFECTION AND IMMUNITY (2011)
A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design
Fikri Y. Avci et al.
NATURE MEDICINE (2011)
Vi-CRM197 as a new conjugate vaccine against Salmonella Typhi
F. Micoli et al.
VACCINE (2011)
Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal Salmonella by blood cells in Africans
Esther N. Gondwe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Reactogenicity and immunogenicity of live attenuated Salmonella enterica serovar Paratyphi A enteric fever vaccine candidates
Kenneth L. Roland et al.
VACCINE (2010)
Protection against Pneumococcal Colonization and Fatal Pneumonia by a Trivalent Conjugate of a Fusion Protein with the Cell Wall Polysaccharide
Ying-Jie Lu et al.
INFECTION AND IMMUNITY (2009)
Mechanisms in the serotype-independent pneumococcal immunity induced in mice by intranasal vaccination with the cell wall polysaccharide
Ying-Jie Lu et al.
MICROBIAL PATHOGENESIS (2009)
Evaluation of a novel Vi conjugate vaccine in a murine model of salmonellosis
Christine Hale et al.
VACCINE (2006)
Capsule-mediated immune evasion: a new hypothesis explaining aspects of typhoid fever pathogenesis
M Raffatellu et al.
INFECTION AND IMMUNITY (2006)
Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children
DG Canh et al.
INFECTION AND IMMUNITY (2004)
Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children
MN Lanh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Regulation of Salmonella typhimurium lipopolysaccharide O antigen chain length is required for virulence;: identification of FepE as a second Wzz
GL Murray et al.
MOLECULAR MICROBIOLOGY (2003)
The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children
FYC Lin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Phase 1 and phase 2 studies of Salmonella enterica serovar Paratyphi A O-specific polysaccharide-tetanus toroid conjugates in adults, teenagers, and 2-to 4-year-old children in Vietnam
EY Konadu et al.
INFECTION AND IMMUNITY (2000)
Share Paper
